Since expression of the EGF system in ovarian tumors relates to poor prognosis as well as to poor response to chemotherapy [32,33], and estradiol mediated activation of GPER attenuates the invasive properties resulting from EGF stimulation [31], a GPER agonist could have therapeutic implications in patients with ovarian cancer. This evidence concerns the gene EGF and ovarian carcinoma.